News

Nicholas Brownstone, MD, and other experts spotlighted cytokine hubs at the 2026 Winter Clinical Miami conference, linking chronic spontaneous urticaria and psoriasis/psoriatic arthritis to smarter targeted treatment choices.

A qualitative study found that hidradenitis suppurativa (HS) significantly influences patients’ daily decisions, emotional health, relationships, and financial stability.

Explore top dermatology conferences and meetings in March 2026 and let us know which ones you'll be attending!

A combined group of ophthalmology and dermatology specialists traveled to communities in Nepal to conduct consultations, procedures, and teaching sessions, and specifically in dermatology, skin malignancy removals, trainings on biologics and JAKs, and melanoma detection demonstrations.

A panel discussion highlights the diagnostic variability, systemic risk, and evolving treatment landscape of GPP.

Rocatinlimab had met primary end points in large phase 3 trials and was previously expected to move toward regulatory submission in 2026.

Priovant Therapeutics' brepocitinib has been assigned a Prescription Drug User Fee Act date in the third quarter of 2026.

The double-blind, randomized, placebo-controlled ARQ-234-131 study will assess safety, tolerability, pharmacokinetics, and early signs of clinical activity.

Skin adverse events linked to immunotherapy may correlate with improved tumor response and survival, underlining their clinical significance.

CLEAR CSCC is evaluating whether low-dose intralesional cemiplimab is noninferior to primary surgery, potentially offering a tissue-sparing alternative to standard surgical management.

Brian Berman, MD, PhD, explains actinic keratosis-to-SCC risk and newer PDT/field therapies that improve clearance with less pain.

Ruiz Dasilva emphasized case-based strategies for managing complex inflammatory dermatoses, highlighted chronic pruritus as an urgent unmet need, and called for more standardized designs for atopic dermatitis trials.

Terrence Keaney, MD, and Dawn Merritt, DO, discuss AI workflows and smart practice systems—plus how a dermatology niche drives referrals and growth.

James Del Rosso, DO, shares rapid-fire insights on mentorship, HS advances, contact dermatitis triggers, and teen skin care marketing concerns.

Catch up on coverage from the final day of Winter Clinical Miami 2026.

Rapid-fire WCM tips included off-label treatment strategies, AI-driven practice management tools, and patient optimization methods.

Real-world data shows Medicare plaque psoriasis patients stay on Sun Pharma’s IL-23 tildrakizumab longer than other systemic therapies.

At Winter Clinical Miami, Lisa Swanson, MD, FAAD, shared practical, prior authorization–free treatment strategies while calling for expanded therapeutic options and earlier research inclusion for children under 12.

At Winter Clinical Miami 2026, Lewitt and Goldenberg share contract, workflow, and ethical industry tips every early career derm needs to thrive.

Nicholas Brownstone, MD, showcased multidisciplinary collaboration and educational podcast initiatives aimed at supporting both dermatology trainees and patients.

Catch up on coverage from the second day of Winter Clinical Miami 2026.

Harrison Nguyen, MD, MBA, MPH, FAAD, shares early career billing, coding, and mentorship tips for dermatologists at Winter Clinical Miami 2026.

A Winter Clinical Miami poster highlights intralesional cemiplimab for early CSCC, showing rapid responses and positive safety versus surgery.

At Winter Clinical Miami 2026, Linda Stein Gold, MD, FAAD, shared acne and rosacea tips and previewed psoriasis oral advances like icotrokinra.

At Winter Clinical Miami 2026, April Armstrong, MD, MPH, spotlights new pediatric topicals and JAK safety insights, plus targeted options for head-and-neck atopic dermatitis.

A poster presented at Winter Clinical Miami 2026 shows tildrakizumab is often preferred for older patients with plaque psoriasis and medically complex comorbidities.

After TMB-001 did not meet its primary end point in the ASCEND trial, LEO Pharma moved to out-license the vehicle formulation, which unexpectedly provided a response in 40% of patients.

Catch up on coverage from the first day of Winter Clinical Miami 2026.

The final case described a young woman with clinically mild hidradenitis suppurativa (HS) but significant emotional and social distress, prompting some of the most passionate discussion across the 3 roundtables.

Mark Lebwohl, MD, shares his Winter Clinical Miami 2026 highlights, including oral psoriasis peptides, atopic dermatitis advances, GLP-1 combos, and more.